Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Politics for Pros- moderated -- Ignore unavailable to you. Want to Upgrade?

To: skinowski who wrote (722711)	8/1/2020 5:45:03 PM
From: frankw1900	1 Recommendation Recommended By kckip Read Replies (1) \| Respond to of 794009

So, Dr Fauci wants a double blind, properly randomized study in order to become a believer in HCQ? So why did he cancel the one that was started by the institution he happens to be running??? Apparently, folk were afraid to enroll in the study - only got 20 enrollees instead of 2000. And so they cancelled it. Believe that and I also got a beautiful bridge in SF I can sell you. Fauci took advantage of months of anti-HCQ bs in the MSM plus recruiters never recruited and that's why they got no enrollment. Fauci is taking advantage of Not-Invented-Here and the complicity of the MSM which is not covering Covid-19 cures and in the cases of online MSM monsters are actively censoring Covid-19 cures. My view is that [1] by blocking, withholding curative treatment some folk are murdering Covid-19 sufferers in hopes it will harm Trump and GOP election outcomes and [2] others, deliberately using badly designed studies are murdering Covid-19 sufferers so they can make a shitload of money selling on-patent meds and vaccines in OECD countries. Can't get away with [2], above, in non-OECD countries because docs, (and everybody who is anybody), in those places have access to tons of info like the following which is all about super cheap drugs they are really familiar with (given away by govts or sold otc in a lot of places). researchgate.net "A comparative observational study on Ivermectin- Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients". Preprint (PDF Available) · June 2020 with 13,081 Reads DOI: 10.13140/RG.2.2.22193.81767/3 Cite this publication Jahirul Islam Xi'an Jiaotong University Show more authors Preprints and early-stage research may not have been peer reviewed yet. Abstract Coronavirus disease 2019 (COVID19) is a WHO declared a global pandemic. From the time of origin to till many antiviral and other drugs are on desperate use to find a cure. We decided to investigate the efficacy of Ivermectin-Doxycycline combination therapy and compare it to the standard HCQ-Azithromycin therapy among the mild to moderate cases of COVID19 patients in Bangladesh. Patients were divided into two groups. Ivermectin 200µgm/kg single dose + Doxycycline 100mg BID for 10d and Hydroxychloroquine 400mg 1st day then 200mg BID for 9days + Azithromycin 500mg daily for 5Days was given to the Group-A and group-B respectively. Treatment outcomes were evaluated on the 5th day in case of asymptomatic patients and the 2nd non-symptomatic day onward from the first day of the drug intake by PCR study. According to this study both the Ivermectin-Doxycycline and HCQ-Azithromycin treatment regimens were found to be effective against SARS-CoV-2 infection. But concerning the treatment outcome, adverse effect, and safety Ivermectin-Doxycycline combination is superior to HCQ-Azithromycin therapy for mild to moderate degree of COVID19 patients in Bangladesh. We strongly believe by rescheduling and increasing the duration of Ivermectin to 3days will certainly decrease the recovery period further than that of our study. This will also prevent disease progression and morbidity to COVID19 patients. Abu Taiub Mohammed Mohiuddin Chowdhury 3.58 Xi'an Jiaotong University Mohammad Shahbaz Md Rezaul Karim 10.7 Hubei University of Chinese Medicine Above study is also summarized in utoob vid:

To: skinowski who wrote (722711)	8/1/2020 6:42:43 PM
From: frankw1900	2 Recommendations Recommended By lightshipsailor Thomas M. Read Replies (1) \| Respond to of 794009

So, Dr Fauci wants a double blind, properly randomized study in order to become a believer in HCQ? So why did he cancel the one that was started by the institution he happens to be running??? Apparently, folk were afraid to enroll in the study - only got 20 enrollees instead of 2000. And so they cancelled it. Believe that and I also got a beautiful bridge in SF I can sell you. Fauci took advantage of months of anti-HCQ bs in the MSM plus recruiters never recruited and that's why they got no enrollment. Fauci is taking advantage of Not-Invented-Here and the complicity of the MSM which is not covering Covid-19 cures and in the cases of online MSM monsters are actively censoring Covid-19 cures. My view is that [1] by blocking, withholding curative treatment some folk are murdering Covid-19 sufferers in hopes it will harm Trump and GOP election outcomes and [2] others, deliberately using badly designed studies are murdering Covid-19 sufferers so they can make a shitload of money selling on-patent meds and vaccines in OECD countries. Can't get away with [2], above, in non-OECD countries because docs, (and everybody who is anybody), in those places have access to tons of info like the following which is all about super cheap drugs they are really familiar with (given away by govts or sold otc in a lot of places). researchgate.net "A comparative observational study on Ivermectin- Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients". Preprint (PDF Available) · June 2020 with 13,081 Reads DOI: 10.13140/RG.2.2.22193.81767/3 Cite this publication Jahirul Islam Xi'an Jiaotong University Show more authors Preprints and early-stage research may not have been peer reviewed yet. Abstract Coronavirus disease 2019 (COVID19) is a WHO declared a global pandemic. From the time of origin to till many antiviral and other drugs are on desperate use to find a cure. We decided to investigate the efficacy of Ivermectin-Doxycycline combination therapy and compare it to the standard HCQ-Azithromycin therapy among the mild to moderate cases of COVID19 patients in Bangladesh. Patients were divided into two groups. Ivermectin 200µgm/kg single dose + Doxycycline 100mg BID for 10d and Hydroxychloroquine 400mg 1st day then 200mg BID for 9days + Azithromycin 500mg daily for 5Days was given to the Group-A and group-B respectively. Treatment outcomes were evaluated on the 5th day in case of asymptomatic patients and the 2nd non-symptomatic day onward from the first day of the drug intake by PCR study. According to this study both the Ivermectin-Doxycycline and HCQ-Azithromycin treatment regimens were found to be effective against SARS-CoV-2 infection. But concerning the treatment outcome, adverse effect, and safety Ivermectin-Doxycycline combination is superior to HCQ-Azithromycin therapy for mild to moderate degree of COVID19 patients in Bangladesh. We strongly believe by rescheduling and increasing the duration of Ivermectin to 3days will certainly decrease the recovery period further than that of our study. This will also prevent disease progression and morbidity to COVID19 patients. Abu Taiub Mohammed Mohiuddin Chowdhury 3.58 Xi'an Jiaotong University Mohammad Shahbaz Md Rezaul Karim 10.7 Hubei University of Chinese Medicine Above study is also summarized in utoob vid: